The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Onco-Nephrology: The Pathophysiology and Treatment of Malignancy-Associated Hypercalcemia
Abstract
Summary: Hypercalcemia complicates the course of 10%–30% of all patients with malignancies and can be a sign of very poor prognosis and advanced malignancy. Prompt recognition of the nonspecific signs and symptoms of hypercalcemia and institution of therapy can be lifesaving, affording the opportunity to address the underlying etiology. The mechanisms of malignancy-associated hypercalcemia generally fall into three categories: humoral hypercalcemia due to secreted factors (such as parathyroid-related hormone), local osteolysis due to tumor invasion of bone, and absorptive hypercalcemia due to excess vitamin D produced by malignancies. The mainstays of therapy for hypercalcemia are aggressive intravenous volume expansion with saline, bisphosphonate therapy, and perhaps loop diuretics. Adjunctive therapy may include calcitonin and corticosteroids. In refractory cases, gallium nitrate and perhaps denosumab are alternatives. In patients presenting with severe AKI, hemodialysis with a low-calcium bath can be effective. In most cases, therapy normalizes calcium levels and allows for palliation or curative therapy of the malignancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825 · cited 4×
“For example, osteoblast cells express estrogen receptors that when occupied with ligand can reduce RANKL and increase OPG (13).”
BackgroundInfluential
Cited by
Essential metals in health and disease
Jomova, K., Makova, M., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., Rhodes, C. J., & Valko, M. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110173 · Cited by 1,121
Acute Kidney Injury in Patients with Cancer
Rosner, M. H., & Perazella, M. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1613984 · Cited by 275
Self-citationAlendronate-modified polymeric micelles for the treatment of breast cancer bone metastasis
Liu, T., Romanova, S., Wang, S., Hyun, M. A., Zhang, C., Cohen, S. M., Singh, R. K., & Bronich, T. K. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01343 · Cited by 34
Metadata
- Authors
- Rosner, M. H., & Dalkin, A. C.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2012-10
- Volume
- 7
- Issue
- 10
- Pages
- 1722-1729
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2148128295
- Cited by
- 178
- References
- 2
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Onco-Nephrology: The Pathophysiology and Treatment of Malignancy-Associated Hypercalcemia. https://app.cochat.ai/papers/10.2215/cjn.02470312
- The paper
- Rosner, M. H., & Dalkin, A. C. (2012). Onco-Nephrology: The Pathophysiology and Treatment of Malignancy-Associated Hypercalcemia. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.02470312
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.